Overview We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. SLK is a proprietary Nan...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001821586-26-000002 | EDGAR | 87K words |
| 2025-02-26 | 2024-12-31 | 0001821586-25-000006 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001821586-24-000008 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0001821586-23-000007 | EDGAR | — |
| 2022-02-17 | 2021-12-31 | 0001213900-22-008253 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001213900-21-019007 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001821586-25-000022 | EDGAR | 27K words |
| 2025-08-05 | 2025-06-30 | 0001821586-25-000018 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001821586-25-000011 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001821586-24-000029 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001821586-24-000025 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001821586-24-000020 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001821586-23-000022 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001821586-23-000015 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001821586-23-000012 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001821586-22-000009 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001821586-22-000006 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001213900-22-027086 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-23 | 0001213900-26-018967 | EDGAR | 4K words |
| 2026-01-08 | 0001213900-26-002344 | EDGAR | — |
| 2025-11-05 | 0001213900-25-106723 | EDGAR | — |
| 2025-11-05 | 0001821586-25-000021 | EDGAR | — |
| 2025-09-29 | 0001213900-25-092614 | EDGAR | — |
| 2025-08-05 | 0001821586-25-000016 | EDGAR | — |
| 2025-06-06 | 0001213900-25-052140 | EDGAR | — |
| 2025-05-12 | 0001821586-25-000009 | EDGAR | — |
| 2025-04-29 | 0001213900-25-036363 | EDGAR | — |
| 2025-04-03 | 0001213900-25-028366 | EDGAR | — |
89 total filings indexed. 61 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001821586 |
| Ticker | MLTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | E9 |
| Website | https://www.moonlaketx.com |
| Listed | 2022-04-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report